Online telehealth company Hims and Hers Health is launching its weight-loss membership and treatment plans in the United ...

Hims & Hers is emerging as a disruptive force in the obesity treatment market, challenging established GLP-1 drug makers. HIMS has aggressively captured market share, often operating in a legal 'grey ...

Zepbound (tirzepatide) and Wegovy (semaglutide) are FDA-approved injectable medications revolutionizing weight management. Both belong to the incretin mimetic drug class but differ in their mechanisms ...

The Food and Drug Administration building is seen on Dec. 10, 2020, in Silver Spring, Md. (AP Photo/Manuel Balce Ceneta, File) WASHINGTON (AP) — For the first time, federal health officials are taking ...

Online telehealth company Hims and Hers Health HIMS.N is launching its weight-loss membership and treatment plans in the UK ...

Hims & Hers Health has sold off ~40% GLP-1 turbulence, but the core growth story remains intact. Read why HIMS stock is a ...

One of largest U.S. telehealth providers expects to ride wave of exploding demand for weight-loss drug semaglutide when it ...

A class-action lawsuit has been filed against CVS Caremark over its decision to stop covering Zepbound, Eli Lilly’s blockbuster GLP-1 drug to treat obesity. When the major pharmacy benefit manager ...

Zepbound (tirzepatide) and Ozempic (semaglutide) are brand-name subcutaneous injections. They’re both prescribed for weight loss and weight management, but only Zepbound has been FDA-approved for this ...

Zepbound (tirzepatide) and Mounjaro (tirzepatide) are prescription drugs used to treat different conditions. Zepbound and Mounjaro are not available as generic drugs. The two drugs have some ...

WASHINGTON (AP) — For the first time, federal health officials are taking aim at telehealth companies promoting unofficial versions of prescription drugs — including popular weight loss medications — ...